2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Dopamine Receptor
  5. Dopamine Receptor Modulator

Dopamine Receptor Modulator

Dopamine Receptor Isoform Comparison

Dopamine Receptor Modulators (19):

Cat. No. Product Name Effect Purity
  • HY-14763
    Cariprazine
    		Modulator 99.83%
    Cariprazine is a novel antipsychotic agent candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).
  • HY-14763A
    Cariprazine hydrochloride
    		Modulator 99.90%
    Cariprazine hydrochloride is a novel antipsychotic agent candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).
  • HY-19733
    Lumateperone tosylate
    		Modulator 99.53%
    Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia.
  • HY-100656
    Desmethyl cariprazine
    		Modulator 98.06%
    Desmethyl cariprazine is an active metabolite of Cariprazine. Cariprazine, an antipsychotic agent candidate, exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (2.6 nM).
  • HY-100658
    Didesmethyl cariprazine
    		Modulator 99.79%
    Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a antipsychotic agent candidate that exhibits high affinity for the D3 and D2 receptors, and moderate affinity for the 5-HT1A receptor.
  • HY-P0079
    Neuromedin N
    		Modulator 99.61%
    Neuromedin N is a potent modulator of dopamine D2 receptor agonist binding in rat neostriatal membranes.
  • HY-148867
    UCM-1306
    		Modulator 99.61%
    UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD).
  • HY-N6960
    L-Stepholidine
    		Modulator 99.79%
    L-Stepholidine (Stepholidine) exhibits mixed dopamine D1 receptor agonist and D2 antagonist properties. L-Stepholidine has neuroprotective effect and inhibits Heroin-induced reinstatement. L-Stepholidine is a potential medication for the research of opiate addiction.
  • HY-107663A
    MIF-1 TFA
    		Modulator 98.01%
    MIF-1 TFA (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 TFA inhibits melanin formation. MIF-1 TFA blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 TFA accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).
  • HY-14763S
    Cariprazine-d6
    		Modulator 98.00%
    Cariprazine-d6 is a deuterium labeled Cariprazine. Cariprazine Cariprazine is an antipsychotic agent that exhibits high affinity for the D3 (Ki of 0.085 nM) and D2 (Ki of 0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki of 2.6 nM)[1].
  • HY-14763S1
    Cariprazine-d8
    		Modulator 99.51%
    Cariprazine-d8 is a deuterium labeled Cariprazine. Cariprazine is a novel antipsychotic agent candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).
  • HY-107663
    MIF-1
    		Modulator
    MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).
  • HY-106660
    BP 897 hydrochloride
    		Modulator 99.84%
    BP 897 hydrochloride is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 hydrochloride displays a high affinity at the dopamine D3 receptor (Ki=0.92 nM) and a 70 times lower affinity at the D2 receptor (Ki=61 nM).
  • HY-103427
    NPEC-caged-dopamine
    		Modulator 99.94%
    NPEC-caged-dopamine is a caged version of dopamine. NPEC-caged-Dopamine was used by applying focal photolysis with UV light (360 nm) to releases dopamine, which leads to D1 receptor activation.
  • HY-127120
    Timiperone
    		Modulator
    Timiperone has a strong affinity for cerebral dopamine D2 receptor. Timiperone has antipsychotic activity, and inhibits stereotyped behaviour. Timiperone can be used for research of schizophrenia.
  • HY-103418
    Dopamine D2 receptor agonist-3
    		Modulator
    Dopamine D2 receptor agonist-3 (compound 3) is a selective D2 receptor partial agonist and Dopamine D3 receptor antagonist (with pEC50 of 8.3 and <5.5 respectively).
  • HY-101583
    NEO 376
    		Modulator 99.23%
    NEO 376 is a selective modulator of 5-HT1 receptor, GABA receptor and dopamine receptor, with anti-psychotic actively.
  • HY-103423
    PAOPA
    		Modulator
    PAOPA, an analog of L-proline-l-leucine-glycine amide (PLG) peptide, is an allosteric modulator of Dopamine D2 Receptor. PAOPA can effectively reduce behavioral abnormalities in rodent models of schizophrenia. PAOPA increases the high affinity dopamine D2 receptor and promotes its binding to agonists.
  • HY-19845A
    Piperidine-MO-1
    		Modulator
    Piperidine-MO-1 is a modulator of dopamine receptor extracted from patent WO/2005/121087A1, compound example 2; exhibits an ED50 of 68 μmol/kg on increase of DOPAC in the rat striatum.